Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0090-8258(75)90038-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cervical Neuroendocrine Carcinoma Presenting as Isolated Large Ovarian Metastasis: A Case Report.
Am J Case Rep
January 2025
Department of Obstetrics and Gynecology, Faculty of Medicine, Dr Soetomo General Hospital, Universitas Airlangga, Surabaya, East Java, Indonesia.
BACKGROUND Neuroendocrine carcinoma (NEC) of the cervix is rare and has high mortality and recurrence rates. The clinical symptoms of cervical NEC, such as abnormal vaginal bleeding and discharge, are similar to those of other cervical cancers. Here, we describe a case involving a 42-year-old woman with cervical NEC accompanied by an isolated large ovarian metastasis.
View Article and Find Full Text PDFThe involvements of intracellular basal calcium and membrane potential in para-phenylenediamine-impaired sperm function.
Transl Androl Urol
December 2024
Center for Reproductive Medicine, Affiliated Hospital of Nantong University, Nantong, China.
Background: Para-phenylenediamine (PPD) is a crystalline solid that belongs to the aromatic amine group, widely used in the manufacturing of various dyes. PPD exhibits toxic effects on female hormone stability, ovarian function, and embryo development. Although studies have shown that PPD exposure can damage oocyte quality in female mice, research on its effects on male reproductive capability, particularly on human sperm quality and function, is limited.
View Article and Find Full Text PDFPredictive impact of clinical factors on chemosensitivity in advanced high-grade serous ovarian carcinoma according to chemotherapy response score.
Medicine (Baltimore)
November 2024
Department of Obstetrics & Gynecology, Chungnam National University School of Medicine, Chungnam National University Sejong Hospital, Sejong, Republic of Korea.
The use of neoadjuvant chemotherapy (NAC) as a first-line therapy for advanced high-grade serous ovarian carcinoma (HGSOC) has increased. However, several studies have reported NAC-induced platinum resistance. This study aimed to evaluate the predictive impact of clinical factors on chemotherapy response score (CRS) and to select patients who would respond well to NAC.
View Article and Find Full Text PDFStudy protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer.
BMJ Open
December 2024
University College London Hospitals NHS Foundation Trust, London, UK
Introduction: Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relapsed, platinum-sensitive high-grade serous or high-grade endometrioid cancer of the ovary, fallopian tube and peritoneum whose disease has progressed at least 6 months after day 1 of the last cycle of platinum-based chemotherapy. AT is a novel, evolutionarily informed approach to cancer treatment, which aims to exploit intratumoral competition between drug-sensitive and drug-resistant tumour subpopulations by modulating drug dose according to a patient's own response to the last round of treatment. ACTOv is the first clinical trial of AT in this disease setting.
View Article and Find Full Text PDFPhase 1 Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3 in Patients with Advanced Solid Tumors.
Clin Cancer Res
January 2025
University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Purpose: Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is essential for the survival and immune sequestration of cancer cells. We conducted a phase 1 study of TTI‑101, a first-in-class, selective small-molecule inhibitor of STAT3, in patients with advanced metastatic cancer.
Patients And Methods: Patients were treated with TTI-101 orally twice daily in 28-day cycles at 4 dose levels (DLs): 3.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!